In general, for women with cancer, controlled ovarian stimulation (COS) for embryo or oocyte cryopreservation is similar to IVF for infertile couples. However, there are some additonal considerations in this population:
What is the general protocol for COS? |
Pre-cycle considerations
Medications
General Protocol Information
Cryopreservation
|
Some additional considerations for COS in cancer patients:
|
|
References
1. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab, 2011 May;96 (5): 1336-43.
2. Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertili Steril, 2010 Feb; 93 (2):391-6.
About the Author
Jennifer Mersereau, MD, MSCI, is an reproductive endocrinologist in the University of North Carolina's Department of Obstetrics and Gynecology. As the Director of the Fertility Preservation Program, she has extensive experience guiding patients and physicians through the oncofertility experience.
This page was last updated March 14, 2012.